Why Is Moderna Stock Up Today?
Moderna kept its 2028 break-even target and 2026 growth guidance at the Morgan Stanley healthcare conference. The stock rose 1.101% in ten minutes on below-normal volume.
- Moderna kept its 2028 break-even target and guidance for up to 10% revenue growth in 2026 at the Morgan Stanley Global Healthcare Conference.
- Measured from 10:39:27 ET, MRNA rose 1.101% in ten minutes on about 0.61 times normal volume.
- The SPDR S&P Biotech ETF was up 1.50% on the session, against Moderna's 1.95%.
Reaction by asset (real prices)
| Asset | 2m before | At release | +1m | +10m | +1m % | +10m % |
|---|---|---|---|---|---|---|
| MRNA Volume 0.6× normal in 15 min |
139.84 | 139.84 | 139.94 | 141.38 | +0.07% | +1.10% |
Moderna stock is up today after the company kept its target of breaking even by 2028 and its guidance for revenue growth of up to 10% in 2026, speaking at the Morgan Stanley Global Healthcare Conference on Monday, September 14, 2026. The reaffirmation crossed MoveSurge's tape at 10:39:27 ET; Moderna rose 0.072% in the first minute and 1.101% in ten, from $139.84 to $141.38, and was up 1.95% at $146.78 by 12:30 ET.
Trading volume in that window ran at about 0.61 times normal.
What Moderna said at the Morgan Stanley conference
- The company kept its 2028 break-even target and its guidance for up to 10% revenue growth this year.
- Its vaccine business now has five approved products: COVID-19, the mFlusiva influenza vaccine, RSV, a flu/COVID combination and mNEXSPIKE, its second-generation COVID vaccine.
- About 3,000 patients have been treated with intismeran, its personalized cancer vaccine, across more than 40 countries, which the company described as commercial-scale manufacturing.
- Pricing, regulatory steps and long-term commercial returns for intismeran are still being worked out.
- President Stephen Hoge pointed to more oncology readouts from lung, melanoma, kidney and bladder cancer studies, and the Marlborough, Massachusetts plant can expand capacity sevenfold with 12 months of lead time.
How Moderna stock reacted, measured against its own record
MoveSurge's record of how MRNA traded in the minutes after each headline crossed the tape. Reactions measured before September 9 use a 15-minute window. Volume against normal is shown only for reactions that began at or after 09:35 ET in regular trading, because pre-market and opening-minute baselines are too small to compare.
| Crossed (ET) | Headline | Before | 1 minute | Terminal move | Volume vs normal |
|---|---|---|---|---|---|
| Sep 14, 10:39 | 2028 break-even target and 2026 growth guidance kept | $139.84 | +0.072% | +1.101% (10 min) | 0.61x |
| Aug 27, 09:31 | Moderna borrows to expand its oncology business | $148.30 | -1.537% | -3.297% (15 min) | — |
| Aug 27, 07:22 | Report: Moderna to offer convertible senior notes | $141.30 | +0.495% | +0.566% (15 min) | — |
| Aug 19, 06:46 | Report: Moderna and Merck melanoma vaccine prevented recurrence | $70.01 | +1.414% | +64.734% (15 min) | — |
| Aug 06, 11:06 | FDA approves Moderna's seasonal flu vaccine | $55.19 | +0.236% | -0.181% (15 min) | 1.9x |
| Jul 31, 07:26 | Norovirus vaccine candidate misses early-success bar at Phase 3 interim | $53.62 | -0.205% | +2.201% (15 min) | — |
The August 19 report moved the stock 64.734% in 15 minutes from $70.01, and by Monday morning the price before the headline had roughly doubled from that level. Monday's reaffirmation carried no new financial targets, and the stock moved 1.101% on below-normal volume.
Biotech rose broadly on the session: the SPDR S&P Biotech ETF was up 1.50%, BioNTech up 3.61% and Pfizer up 0.38%, so most of Moderna's 1.95% gain matched its sector.
Earlier catalysts
August 19, 2026: Phase 3 melanoma result. Merck and Moderna reported that the Phase 3 INTerpath-001 trial of intismeran autogene with KEYTRUDA met its recurrence-free survival and distant metastasis-free survival endpoints in resected melanoma. Measured from the official release, Moderna went from $69.99 to $109.00 within 15 minutes, 55.737% higher. The full record is on the INTerpath programme page.
July 31, 2026: norovirus interim analysis and second-quarter results. Coverage is on the Moderna second-quarter page.
Why is Moderna stock up today?
Moderna kept its 2028 break-even target and its guidance for up to 10% revenue growth in 2026 at the Morgan Stanley Global Healthcare Conference on September 14, 2026. Measured from 10:39:27 ET, the stock rose 1.101% in ten minutes, and it was up 1.95% on the session at 12:30 ET.
When does Moderna expect to break even?
In 2028. The company kept that target at the Morgan Stanley conference and said its vaccine business now has five approved products.
How did Moderna stock react to the Morgan Stanley conference?
Moderna rose 0.072% in the first minute and 1.101% in ten, from $139.84 to $141.38, on about 0.61 times normal volume. The SPDR S&P Biotech ETF was up 1.50% on the session.
How many patients has Moderna treated with intismeran?
About 3,000 patients in more than 40 countries, Moderna said at the conference.
Sources
-
Moderna at Morgan Stanley conference: oncology gains and vaccine growth
— Investing.com
At the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, Moderna kept its 2028 break-even target, reiterated guidance for up to 10% revenue growth this year, said its vaccine business has five approved products, said about 3,000 patients have been treated with intismeran across more than 40 countries, and said pricing, regulatory steps and long-term commercial returns are still being worked out.
-
Moderna's Cancer Vaccine Win Fuels Broad Push Across Tumor Types
— MarketBeat
President Stephen Hoge pointed to the Phase 3 adjuvant melanoma result and further oncology readouts in lung, melanoma, kidney and bladder cancer; the Marlborough, Massachusetts plant can expand capacity sevenfold with 12 months of lead time.
Never miss the next market-moving story
Follow the core market-moving feed across equities, macro, currencies and commodities. Your subscription includes recorded price reactions, search, watchlists, alerts and research tools.
Start Pro Watch live headlines -- free